MDGL — Madrigal Pharmaceuticals, Inc.
8 mentions in the last 24 hours · 0.04% of all mentions
Why people talked about MDGL (2026-11-03)
- Madrigal Pharmaceuticals reported Q3 2026 financial results, with revenue of $431.3M beating estimates.
- The company reported an EPS of $1.83, significantly exceeding the -$1.09 analyst estimate.
- The stock experienced a 10.63% surge with volume 4.0 times its normal level following the earnings news.
| Bluesky | 6 | community |
| GDELT | 1 | news |
| SEC EDGAR 8-K | 1 | filings |